Immunotherapy-Radiation combo studied for bladder cancer
NCT ID NCT03747419
First seen Nov 01, 2025 · Last updated Apr 29, 2026 · Updated 26 times
Summary
This study looked at adding the immunotherapy drug avelumab to standard radiation therapy for people with muscle-invasive bladder cancer who cannot take the chemotherapy drug cisplatin. The goal was to see if the combination could completely eliminate signs of cancer. The study enrolled 14 participants but was stopped early. It was sponsored by Dana-Farber Cancer Institute.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02215, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02115, United States
Conditions
Explore the condition pages connected to this study.